CROs

Another big CRO deal in the works? Thermo Fisher in talks to acquire PPD for $15B+ — report
Another big CRO deal in the works? Thermo Fisher in talks to acquire PPD for $15B+ — report
Endpoints
ThermoFisher Scientific
PPD
M&A
CROs
Flag link:
The CRO megamerger is back as Icon snaps up PRA Health for $12B
The CRO megamerger is back as Icon snaps up PRA Health for $12B
Fierce Biotech
M&A
CROs
Icon Biosciences
PRA Health
Flag link:
GSK sells vaccine laboratory activities to Nexelis
GSK sells vaccine laboratory activities to Nexelis
Biopharma Reporter
GSK
CROs
Nexelis
vaccines
Flag link:
Charles River bags antibody discovery-focused Distribution Bio for $104M, signaling return to pre-pandemic buyout spree
Charles River bags antibody discovery-focused Distribution Bio for $104M, signaling return to pre-pandemic buyout spree
Endpoints
Charles River Labs
CROs
M&A
Distribution Bio
Flag link:
Galapagos sells off Fidelta as CRO activities 'no longer fit with its strategy'
Galapagos sells off Fidelta as CRO activities 'no longer fit with its strategy'
Fierce Biotech
Galapagox
Fidelta
CROs
R&D
Flag link:
Syneos Health to Acquire Synteract, Expand Its Global Expertise
Syneos Health to Acquire Synteract, Expand Its Global Expertise
BioSpace
CROs
M&A
Syneos Health
Synteract
Flag link:
CRO market to recover, using 'hybrid trials,' with revenue hitting $64B by 2024: report
CRO market to recover, using 'hybrid trials,' with revenue hitting $64B by 2024: report
Fierce Biotech
CROs
clinical trials
hybrid clinical trials
COVID-19
pandemic
Flag link:
PPD squeezes out a revenue growth despite COVID-19 disruption
PPD squeezes out a revenue growth despite COVID-19 disruption
Fierce Biotech
PPD
CROs
earnings
Flag link:
Pfizer reups PPD deal in a contract research pact spree
Pfizer reups PPD deal in a contract research pact spree
Fierce Biotech
Pfizer
R&D
CROs
PPD
Flag link:
Pfizer doubles down on Syneos Health with new services pact
Pfizer doubles down on Syneos Health with new services pact
Fierce Biotech
Pfizer
CROs
Syneos Health
Flag link:
Charles River expects hit of up to $215M from COVID-19
Charles River expects hit of up to $215M from COVID-19
Fierce Biotech
Charles River Labs
CROs
COVID-19
pandemic
Flag link:
Icon to slash costs amid pandemic as 65% of its trial sites disrupted by COVID-19
Icon to slash costs amid pandemic as 65% of its trial sites disrupted by COVID-19
Fierce Biotech
ICON
COVID-19
layoffs
clinical trial recruitment
clinical trials
pandemic
CROs
Flag link:
Life science companies combine to form COVID-19 research database
Life science companies combine to form COVID-19 research database
Fierce Biotech
CROs
life sciences
data analytics
R&D
database
Flag link:
Pfizer signs up for longer pact with Icon, pens extra 2-year clause
Pfizer signs up for longer pact with Icon, pens extra 2-year clause
Fierce Biotech
Pfizer
ICON
CROs
R&D
Flag link:
J&J's favorite CAR-T developer, currently owned by a Chinese CRO, is laying the groundwork for US IPO
J&J's favorite CAR-T developer, currently owned by a Chinese CRO, is laying the groundwork for US IPO
Endpoints
CAR-T
IPOs
GenScript
CROs
China
JNJ
Flag link:
CROs, clinical researchers brace for impact of coronavirus shutdown across China
CROs, clinical researchers brace for impact of coronavirus shutdown across China
Fierce Biotech
China
coronavirus
COVID-19
clinical trials
CROs
Flag link:
Drug research firm PPD prices IPO at top end of target
Drug research firm PPD prices IPO at top end of target
Reuters
IPOs
CROs
PPD
Flag link:
PPD Files the Paperwork for $100 Million IPO
PPD Files the Paperwork for $100 Million IPO
CP WIre
PPD
CROs
IPOs
Flag link:
PPD Files the Paperwork for $100 Million IPO
PPD
CROs
IPOs
Flag link:
Worldwide Clinical Trials to Use Novel Platform to Address Phase I Trial Challenges
Worldwide Clinical Trials to Use Novel Platform to Address Phase I Trial Challenges
Xtalks
Worldwide Clinical Trials
clinical trials
CROs
Flag link:

Pages